FPN Logo
Support us in advancing a cure!
FPN is a non-profit organization that is solely funded by our readers.
DONATE NOW
FEBRUARY 2019
In January 2019, a  study was published by the Journal of the Peripheral Nervous System
on the design and characteristics of patient data collected from the  Peripheral Neuropathy Research Registry (PNRR) . This is the first ever overall study performed on this Patient Registry and one that truly highlights the importance of this dataset for current and future research in the field of peripheral neuropathy.

To read more and gain access to the original study, click here.
While most people recognize diabetes as a potential cause of peripheral neuropathy, patients may be surprised to find that they are at risk for peripheral neuropathy if they are diagnosed with metabolic syndrome- even before they are fully diagnosed as diabetic.
 
Dr. Shanna Patterson explains metabolic syndrome, why we should be concerned about it, and what we can do about it- as well as provides information on a clinical study for patients who have been diagnosed with metabolic syndrome.
 
Click here for more information.
Gene Therapy Blocks Peripheral Nerve Damage in Mice
A new study from Washington University School of Medicine in St. Louis has
developed a method to block the nerve fiber breakdown in mice using gene therapy that could have significant impact on the treatment of peripheral neuropathy and other nerve-related conditions.

You can read more about this study and its potential implications here.
Understanding Neuromodulation
Neuromodulation refers to the effect on pain sensations when stimuli is applied to nerves that do not transmit pains signals in order to affect the nerves that do transmit pain signals. It is the theory behind TENS units and other devices.   While some people do experience relief, little is known as to exactly why.

Johns Hopkins announced the start of a series of research endeavors to study this effect, and get a better understanding of how and why neuromodulation works, in order to be able to develop better treatment for patients with chronic pain.

For more information,  read the publication here .
Congratulations, FPN Board President Lou Mazawey !
FPN's very own Board President and Groom Law Group's Principal Lou  Mazawey was named by Washingtonian magazine in its
December 2018 issue as one of Washington, DC's Best Lawyers: Tax. 

Join us in wishing Lou congratulations on this accomplishment!
Carpal Tunnel Syndrome Trial
A non-invasive device has been developed to alleviate symptoms of carpal tunnel syndrome and is being investigated in an NIH-funded clinical trial

If you or someone you know has been diagnosed with carpal tunnel syndrome and have the diagnosis confirmed via a nerve conduction study, then you/they may be eligible to join this study.   Find out more.
Looking for more access?  More information? 
Premium Members of the Foundation for Peripheral Neuropathy get the latest peripheral neuropathy information and exclusive access to valuable resources - all while supporting the cause.  If you have not yet joined, it's easy to do so! 
Annual donations of at least $30 qualify you for Premium Membership.
If you're already a Premium Member, thank you for advancing our mission 
to raise awareness and find a cure!!!  
Disclaimer: The information contained in this e-news is not intended to substitute for informed medical advice. You should not use this information to diagnose or treat a health problem or disease without consulting a qualified health care provider. You are strongly encouraged to consult a neurologist with any questions or comments you may have regarding your condition. The best care can only be given by a qualified provider who knows you personally.
By clicking "unsubscribe" below, you will no longer receive ANY communication from the Foundation.  If you prefer to stop receiving our
monthly E-News, please contact us at info@tffpn.org to be removed from this list.